GS 4571
Alternative Names: GS-4571Latest Information Update: 27 Sep 2024
Price :
$50 *
At a glance
- Originator Gilead Sciences
- Class Antihyperglycaemics; Obesity therapies; Small molecules
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Obesity; Type 2 diabetes mellitus
Most Recent Events
- 28 Aug 2024 Phase-I clinical trials in Obesity in USA (PO) (NCT06562907)
- 28 Aug 2024 Phase-I clinical trials in Type 2 diabetes mellitus in USA (PO) (NCT06562907)
- 20 Aug 2024 Gilead Sciences plans a phase I trial for Type 2 diabetes mellitus and Obesity (PO) in August 2024 (NCT06562907)